Kyleena
Alternative Name: LNG Contraceptive IUS (LCS); LCS16
Description: A new low-dose levonorgestrel contraceptive intrauterine systems (LCS), Kleena(R) delivers 16 µg/24h and is effective for 5 years. Kyleena is similar to Mirena, but with a drug content of only 19.5 mg LNG (as opposed to 52mg LNG).
Product Details
Duration: 5 years
Regimen:
Dose: 16 microg/24 h
Active Pharmaceutical Ingredient (API):
Status Details
Status Details: - The U.S. Food and Drug Administration (FDA) approved Kyleena in September 2016.
- Kyleena will be available in the U.S. in October 2016.
- In Nov. 2015, Bayer preregistered the product for contraception in the European Union.
- The U.S. Food and Drug Administration (FDA) approved Kyleena in September 2016.
- Kyleena will be available in the U.S. in October 2016.
- In Nov. 2015, Bayer preregistered the product for contraception in the European Union.
Additional Information
References: Kyleena product website: https://www.kyleena-us.com/
ClinicalTrials.gov Identifier: NCT00528112
Kyleena product website: https://www.kyleena-us.com/
ClinicalTrials.gov Identifier: NCT00528112